INTEGRA Biosciences and Parse Biosciences have collaborated to automate single cell RNA sequencing (scRNA-seq) using the ASSIST PLUS pipetting robot.
The partnership combines Parse Biosciences’ Evercode™ combinatorial barcoding technology with INTEGRA’s liquid handling expertise, making sequencing workflows faster and more reproducible.
scRNA-seq is vital for advancing knowledge and therapies in fields like developmental biology, neurology, and cancer.
Parse Biosciences’ Evercode technology allows for millions of cells to be prepared and sequenced in parallel without individual cell isolation.
The collaboration has made automation and scRNA-seq more accessible and cost-effective for labs of all sizes, reducing hands-on time and manual pipetting steps significantly.
INTEGRA Biosciences and Parse Biosciences have teamed up to create an innovative solution for automating single cell RNA sequencing (scRNA-seq) using the ASSIST PLUS pipetting robot. By combining Parse Biosciences’ Evercode™ technology with INTEGRA’s liquid handling expertise, labs in academia and industry can now streamline and standardize their sequencing workflows for faster throughput and more consistent results. This collaboration aims to make scRNA-seq more accessible to labs of all sizes and budgets, ultimately benefiting research in fields such as developmental biology, neurology, diabetes, cardiovascular disease, and cancer.
Parse Biosciences, a Seattle-based company specializing in tools for scRNA-seq at scale, developed the Evercode technology to enable the preparation and sequencing of a million cells or nuclei in parallel without the need for individual cell isolation. INTEGRA’s ASSIST PLUS, equipped with the D-ONE single channel pipetting module and an 8 channel VIAFLO electronic pipette, automates the Evercode protocol, reducing hands-on time by 75% and manual pipetting steps by 85%. This automation not only speeds up workflows and minimizes human errors but also opens doors for further advancements in single cell sequencing, such as the potential automation of additional workflows like Evercode TCR and Evercode BCR for T-cell and B-cell receptor profiling.
Dr. Charlie Roco, Co-founder and CTO of Parse Biosciences, expressed excitement about the successful collaboration with INTEGRA and the potential to automate the remainder of the scRNA-seq protocol on the pipetting platform in the near future. This development signifies a significant step forward in making cutting-edge technologies more accessible and cost-effective for researchers, ultimately leading to more reliable and high-quality scRNA-seq data for various biomedical applications.
